Skip to main content
Journal of Orthopaedics and Traumatology

Official Journal of the Italian Society of Orthopaedics and Traumatology

Table 1 Demographic and baseline data for patients presenting any periprosthetic fracture (PPF), humeral shoulder PPF, pelvic hip PPF, femoral hip PPF, femoral knee PPF, tibial knee PPF, and tibial ankle PPF

From: Optimizing periprosthetic fracture management and in-hospital outcome: insights from the PIPPAS multicentric study of 1387 cases in Spain

 

PPF

Humeral shoulder

Pelvic hip

Femoral hip

Femoral knee

Tibial knee

Tibial ankle

N = 1387

N = 32

N = 31

N = 720

N = 544

N = 41

N = 10

Age—years

 Median (IQR)

84 (77–89)

78 (71.75–81)

81 (72.5–85)

85 (78–90)

85 (78–90)

77 (70–84)

77 (73.25–79)

Gender—no. (%)

 Female

1041 (75.1)

26 (81.2)

21 (67.7)

477 (66.2)

466 (85.7)

36 (87.8)

7 (70)

 Male

346 (24.9)

6 (18.8)

10 (32.3)

243 (33.8)

78 (14.3)

5 (12.2)

3 (30)

Place of residency—no. (%)

 Own home

1135 (81.8)

31 (96.9)

28 (90.3)

586 (81.4)

436 (80.1)

35 (85.4)

10(100)

 Nursing home

229 (16.5)

0 (0)

3 (9.7)

124 (17.2)

96 (17.6)

6 (14.6)

0 (0)

 Hospital

7 (0.5)

0 (0)

0 (0)

2 (0.3)

5 (0.9)

0 (0)

0 (0)

 N/A

16 (1.2)

1 (3.1)

0 (0)

8 (1.1)

7 (1.3)

0 (0)

0 (0)

Pre-fracture mobility*—no. (%)

 1

385 (27.8)

25 (78.5)

13 (41.9)

178 (24.7)

147 (27)

11 (26.8)

5 (50)

 2

299 (21.6)

3 (9.4)

9 (29)

164 (22.8)

113 (20.8)

6 (14.6)

2 (20)

 3

225 (16.2)

1 (3.1)

2 (6.5)

141 (19.6)

71 (13.1)

8 (19.5)

2 (20)

 4

287 (20.7)

0 (0)

3 (9.7)

151 (21)

120 (22.1)

12 (29.3)

0 (0)

 5

177 (12.8)

2 (6.2)

4 (12.9)

78 (10.8)

89 (16.4)

4 (9.8)

0 (0)

 N/A

14 (1)

1 (3.1)

0 (0)

8 (1.1)

4 (0.7)

0 (0)

1 (10)

Pfeiffer’s SPMSQ—no.

 Median (IQR)

3 (0–6)

1 (0–1.5)

2 (0–4)

3 (1–6)

3 (0–7)

0.5 (0–3)

0 (0–1)

 N/A

74 (5,3)

1 (3.1)

2 (6.5)

35 (4.9)

31 (5,7)

3 (7.3)

1 (10)

CFS—no.

       

 Median (IQR)

5 (3–6)

3 (2.75–5)

4 (3–5.5)

5 (4–6)

5 (3–7)

5 (3–6)

3 (2.25–3)

 N/A

30 (2.2)

0 (0)

0 (0)

17 (2.4)

11 (2)

1 (2.4)

0 (0)

ASA—no. (%)

 1

11 (0.8)

1 (3.1)

0 (0)

7 (1)

3 (0.6)

0 (0)

0 (0)

 2

368 (26.5)

17 (53.1)

9 (29)

170 (23.6)

148 (27.2)

12 (29.3)

6 (60)

 3

728 (52.5)

11 (34.4)

12 (38.7)

391 (54.3)

292 (53.7)

17 (41.5)

4 (40)

 4

154 (11.1)

1 (3.1)

2 (6.5)

77 (10.7)

72 (13.2)

2 (4.9)

0 (0)

 5

3 (0.2)

0 (0)

0 (0)

1 (0.1)

2 (0.4)

0 (0)

0 (0)

 N/A

123 (8.9)

2 (6.2)

8 (25.8)

74 (10.3)

27 (5)

10 (24.4)

0 (0)

Charlson comorbidity index—no.

       

 Median (IQR)

5 (4–7)

4 (3–5)

5 (4– 6.5)

5 (4–7)

5 (4–7)

5 (3–7)

3.5 (3–4)

Osteoprotective treatment—no. (%)

 No treatment

930 (67.1)

22 (68.8)

17 (54.8)

492 (68.3)

359 (66)

29 (70.7)

6 (60)

 Osteoprotective treatment^

457 (32.9)

10 (31.2)

14 (45.2)

228 (31.7)

185 (34)

12 (29.3)

4 (40)

 Anti-resorptive

102 (22.3)

2 (20)

3 (21.4)

54 (23.7)

36 (19.5)

5 (41.7)

1 (25)

 Bone-forming

19 (4.2)

0 (0)

1 (7.1)

9 (3.9)

8 (4.3)

1 (8.3)

0 (0)

 Calcium

262 (57.3)

4 (40)

7 (50)

135 (59.2)

106 (57.3)

5 (41.7)

2 (50)

 Vitamin D

379 (82.9)

8 (80)

13 (92.9)

194 (85.1)

146 (78.9)

11 (91.7)

4 (100)

Antiaggregant or anticoagulant medication—no. (%)

 None

864 (62.3)

29 (90.6)

22 (71)

431 (59.9)

339 (62.3)

29 (70.7)

9 (90)

 Acenocumarol or NOAC or PAA

494 (35.6)

3 (9.4)

7 (22.6)

274 (38.1)

194 (35.7)

11 (26.8)

1 (10)

 Double

19 (1.4)

0 (0)

2 (6.5)

12 (1.7)

4 (0.7)

1 (2.4)

0 (0)

 N/A

10 (0.7)

0 (0)

0 (0)

3 (0.4)

7 (1.3)

0 (0)

0 (0)

Hb at admission (g/dL)—no.

       

 Median (IQR)

12.2 (10.9–13.4)

12.9 (11.4–13.8)

12.7 10.9–13.2)

12.2 (11–13.4)

12.1 (10.8–13.35)

12.4 (10.8–13.6)

12.3 (11.7–13.5)

 N/A

19 (1.4)

0 (0)

2 (6.5)

13 (1.8)

1 (0.2)

2 (4.9)

1 (10)

Time between last prosthesis and PPF (months)—no. (%)

  < 1 month

36 (2.6)

2 (6.3)

1 (3.2)

25 (3.5)

6 (1.1)

1 (2.4)

1 (10)

 From 1  to < 6 months

62 (4.5)

1 (3.1)

3 (9.7)

34 (4,7)

17 (3.1)

5 (12.2)

1 (10)

 From 6  to < 12 months

33 (2.4)

0 (0)

2 (6.5)

17 (2.4)

11 (2)

2 (4.9)

1 (10)

 From 1 to < 5 years

217 (15.6)

16 (50)

5 (16.1)

101 (14)

86 (15.8)

5 (12.2)

1 (10)

  ≥ 5 years

993 (71.6)

11 (34.4)

20 (65.4)

518 (71.9)

407 (74.8)

27 (65.9)

5 (50)

 N/A

46 (3.3)

2 (6.3)

0 (0)

25 (3.5)

17 (3.1)

1 (2.4)

1 (10)

  1. Humeral elbow and patellar PPF are not detailed (n = 4 and n = 5)
  2. IQR interquartile range, N/A not available, Pfeiffer′s SPMSQ Pfeiffer′s Short Portable Mental Status Questionnaire, CFS clinical frailty scale, ASA American Society of Anesthesiologists (ASA) physical status classification system, NOAC new oral anti-coagulant, PAA platelet anti-aggregant, Hb haemoglobin
  3. *Pre-fracture mobility scale: 1, completely independent gait; 2, independent gait outdoors with one technical aid; 3, independent gait outdoors with two technical aids; 4, independent gait indoors only, with or without aids; 5, no mobility at all or only with the help of two other people
  4. ^ Osteoprotective treatment: the percentage for each individual treatment was calculated with respect to the total number of patients receiving osteoprotective treatment
Back to article page